2-(1-methyl-1H-1,2,3-triazol-4-yl)propan-2-ol | 1599567-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1-methyl-1H-1,2,3-triazol-4-yl)propan-2-ol
• 英文别名: 2-(1-methyltriazol-4-yl)propan-2-ol
• CAS: 1599567-63-1
• 化学式: C₆H₁₁N₃O
• 分子量: 141.17
• InChiKey: IZYJJPFDVHGKAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20170073343A1

  公开（公告）日：2017-03-16

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R 1 , R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了新颖的咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啉衍生物的化合物(I)及其药学上可接受的盐，其中R1、R1a、R1b、R2、R4、R5、R6、X和Z如规范中所定义。该发明还涉及包含化合物(I)的药物组合物，以及利用这些化合物治疗与LRRK2相关的疾病，如神经退行性疾病包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• Heterogeneous Copper Nanocatalyst and Manufacturing Methods Thereof
  申请人：Park Jai Wook

  公开号：US20110172417A1

  公开（公告）日：2011-07-14

  This invention relates to a heterogeneous copper nanocatalyst composed of copper nanoparticles immobilized on a boehmite support, a method of preparing the same, and the use thereof. The copper nanocatalyst composed of the copper nanoparticles supported on boehmite exhibits excellent performance in a Huisgen cycloaddition reaction and an A3 coupling reaction of aldehyde, amine and alkyne. The copper nanocatalyst is able to be prepared in a large scale and shows superior reactivity even when used in a small amount under mild conditions without an additive in an organic reaction. This heterogeneous catalyst is easy to separate and reuse after the reaction.

  本发明涉及一种异质铜纳米催化剂，由铜纳米颗粒固定在氧化铝支撑物上组成，以及其制备方法和使用方法。铜纳米颗粒支撑在氧化铝上的铜纳米催化剂在Huisgen环加成反应和醛、胺和炔的A3偶联反应中表现出优异的性能。铜纳米催化剂能够在大规模下制备，并且即使在有机反应中在温和条件下无添加剂时，使用少量也表现出优异的反应活性。这种异质催化剂易于在反应后分离和重复使用。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070225285A1

  公开（公告）日：2007-09-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和包含这些化合物的药物组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这些FLAP调节剂的方法，单独或与其他化合物组合使用，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或症状。
• Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
  申请人：Pfizer Inc.

  公开号：US10039753B2

  公开（公告）日：2018-08-07

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了式 (I) 的新型咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物及其药学上可接受的盐类 其中 R1、R1a、R1b、R2、R4、R5、R6、X 和 Z 如说明书中所定义。本发明还涉及包含式（I）化合物的药物组合物，以及该化合物在治疗与 LRRK2 有关的疾病中的用途，如神经退行性疾病，包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP3350178B1

  公开（公告）日：2021-10-20